


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On February 26, 2007

TOWNSEND and TOWNSEND and CREW LLP

By: Corinna Joss
Corinna Joss



PATENT
Attorney Docket No.: 015280-290110US
Client Ref. No.: E-171-1996/0-US-03
Customer No.: 45115

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KLIMPEL *et al.*

Application No.: 09/853,530

Filed: May 9, 2001

For: TARGETING ANTIGENS TO THE
MHC CLASS I PROCESSING
PATHWAY WITH AN ANTHRAX
TOXIN FUSION PROTEIN

Confirmation No. 7146

Examiner: Schwadron, Ronald B.

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed January 8, 2007, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing along with a Petition for a two-month extension of time to extend the period of response to on or before March 8, 2007. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Appl. No. 09/853,530

Amdt. dated February 26, 2007

Reply to Office Communication of January 8, 2007

PATENT

Amendments to the Specification begin on page 3 of this paper.

Remarks begin on page 4 of this paper.